PubMed · 4111597
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
A K Foulis. 1972-04-15. Leucocyte-migration test.. https://doi.org/10.1016/s0140-6736(72)90821-5
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Examination of the interactions between various cells of the vascular wall and blood components are essential for understanding different pathophysiological processes. Such investigations require appropriate techniques. Several groups have attempted to establish different methods. In all blood vessels except capillaries, endothelial cells (EC) and smooth muscle cells (SMC) coexist and interact very closely. The current study describes a new 3-dimensional triple chamber migration assay, studying leukocyte migration through human endothelial cell monolayers (ECM) towards human SMC layers simultaneously. To test the new assay, SMC-layers were prestimulated with different concentrations of tumor necrosis factor alpha (TNF-alpha, 1 ng/ml, 10 ng/ml, 100 ng/ml) over 6 hours. Then, two microporous membranes, a collecting membrane and a third membrane with cultured ECM, were inserted. Freshly isolated peripheral blood mononuclear cells (PBMNC) were seeded on the ECM and transmigrated cells were measured after further 3 hours incubation. The migration against non stimulated SMC-layers was used as control. Prestimulated SMC-layers led to a dose dependent increase of PBMNC migration into the subendothelial cell space. Antibodies against interleukin-1 reduced the PBMNC migration. In conclusion, this assay allows to study cell migration into the subendothelial space and interactions between different vascular cells. Moreover, this assay can also be used for studies on other cell-cell interactions in man.
The increased migration of peripheral blood mononuclear cells (PBMNCs) across a fibronectin (FN) matrix in response to the chemokines RANTES, MIP-1 alpha and MCP-1 is antagonized by interferon-beta-1b (IFN beta-1b). MCP-1 treatment of PBMNCs elevates their mRNA level and secretion of a matrix degrading enzyme, matrix metalloproteinase (MMP)-9, which is abrogated by IFN beta-1b. The clinical benefits of IFN beta-1b treatment in multiple sclerosis patients may in part be a result of this drug's ability to decrease the migration of PBMNCs in spite of a chemotactic gradient. Furthermore, the elevation of MMP-9 production by PBMNCs may be an important mechanism of action of chemokines.
A 47-year-old woman who had been treated for chronic hepatitis was admitted to our hospital because of a productive cough that developed after she took Pien Tze Huang. A chest X-ray film revealed a reticular shadow in both lower lung fields and pulmonary-function tests showed a restrictive pattern. Pien Tze Huang was discontinued and the patients condition was observed. No other treatment was given, and the patient's symptoms, laboratory data, chest roentgenographic findings, and pulmonary function gradually improved. The result of a leukocyte migration inhibition test was positive for Pien Tze Huang, and the final diagnosis was drug-induced pneumonia due to Pien Tze Huang. We know of no previous report of Pien Tze Huang-induced pneumonia.